Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2023; 18(04): 777-781
DOI: 10.1055/s-0043-1777271
Original Article

A Comparative Retrospective Survival Analysis Study of Brain Tumor Patients in Age Less Than or Equal to 50 Years versus More Than 50 Years of Age

Radha Kesarwani
1   Department of Radiotherapy, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
,
Astha Singh 
2   Department of Interventional Radiology, Lal Path, New Delhi, India
,
Mohammad Aqueel
1   Department of Radiotherapy, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
,
Virendra Singh
1   Department of Radiotherapy, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
,
Gyan Prakash
3   Department of SPM, Moti Lal Nehru Medical College, Prayagraj, Uttar Pradesh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Approximately 2.5% of fatalities from cancer are caused by brain tumors. Even though there is literature regarding prognostic factor of adult brain tumor, studies often resort to Western demographics. Hence, we conducted this retrospective observational study to compare the demographic characteristics and prognosis in patients of glial tumors in Indian population with histological diagnosis with respect to age.

Materials and Methods A single-center retrospective observational study with 76 patients of glioma who had been treated with surgery combined with radiotherapy with or without chemotherapy was conducted. Group I patients were aged less than or equal to 50 years and group II more than 50 years of age. There were 28 patients in group I and 48 in group II. Postoperatively, external beam radiation therapy was delivered in a conventional fraction (1.8 Gy/fraction, five fractions/week) using telecobalt 60. Ill patients who presented with grade III and IV gliomas received oral chemotherapy temozolomide at a dose of 100 mg daily during course of radiotherapy.

Results The median age of the patients at the time of diagnosis was 45.0 years. More cases of hematologic toxicity occurred in group I than in group II. Total 55 patients were alive at 1-year follow-up (11 in group I and 44 in group II).

Conclusion Grade I and II gliomas were predominant in less than 50 years of age and grade III and IV were predominant in more than 50 years age. Male preponderance was seen in age group of more than 50 years (68%). Overall survival and disease-free survival were better for patients aged less than 50 years.

Keywords

brain tumor - cancer - glioma - prognosis - radiotherapy

Ethical Approval Statement

Ethical clearance was taken by Ethical committee of MLNMC, Prayagraj.


Funding

None.




Publication History

Article published online:
29 December 2023

© 2023. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ostrom QT, Gittleman H, Farah P. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-oncol 2013; 15 (Suppl 2, Suppl 2): ii1-ii56
    CrossrefPubMedGoogle Scholar
  • 2 Gilbert MR, Dignam JJ, Armstrong TS. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 3 Chinot OL, Wick W, Mason W. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (08) 709-722
    CrossrefPubMedGoogle Scholar
  • 4 Yang LS, Huang FP, Zheng K. et al. Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients. J Neurooncol 2010; 100 (01) 113-120
    CrossrefPubMedGoogle Scholar
  • 5 Phoenix TN, Patmore DM, Boop S. et al. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell 2016; 29 (04) 508-522
    CrossrefPubMedGoogle Scholar
  • 6 Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 2007; 25 (16) 2306-2312
    CrossrefPubMedGoogle Scholar
  • 7 Sause WT, Scott C, Taylor S. et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87 (03) 198-205
    CrossrefPubMedGoogle Scholar
  • 8 Ries LA, Melbert D, Krapcho M. et al. SEER Cancer Statistics Review, 1975–2005. Bethesda, MD: National Cancer Institute; 2008: 2999
    Google Scholar
  • 9 Moersch FP, Craig WM, Kernohan JW. Tumors of the brain in aged persons. Arch Neurol Psychiatry 1941; 45 (02) 235-245
    CrossrefGoogle Scholar
  • 10 Friedman H, Odom GL. Expanding intracranial lesions in geriatric patients. Geriatrics 1972; 27 (04) 105-115
    PubMedGoogle Scholar
  • 11 Twomey C. Brain tumours in the elderly. Age Ageing 1978; 7 (03) 138-145
    CrossrefPubMedGoogle Scholar
  • 12 Tomita T, Raimondi AJ. Brain tumors in the elderly. JAMA 1981; 246 (01) 53-55
    CrossrefPubMedGoogle Scholar
  • 13 Godfrey JB, Caird FI. Intracranial tumours in the elderly: diagnosis and treatment. Age Ageing 1984; 13 (03) 152-158
    CrossrefPubMedGoogle Scholar
  • 14 Lowry JK, Snyder JJ, Lowry PW. Brain tumours in the elderly. Arch Neurol 1998; 55: 922-928
    PubMedGoogle Scholar
  • 15 Patel PN, Bhattacharya J, Vyas RK, Suryanarayana U. An audit of brain tumor patients treated in 5 years at a single institute: our regional cancer center experience. J Cancer Res Ther 2020; 16 (06) 1466-1469
    CrossrefPubMedGoogle Scholar
  • 16 Lin Z, Yang R, Li K. et al. Establishment of age group classification for risk stratification in glioma patients. BMC Neurol 2020; 20 (01) 310
    CrossrefPubMedGoogle Scholar
  • 17 Wang GM, Cioffi G, Patil N. et al. Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro-oncol 2022; 24 (02) 302-310
    CrossrefPubMedGoogle Scholar